UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Recent insights into the molecular basis of Fanconi anemia: genes, modifiers, and drivers

International journal of hematology, 2017-09, Vol.106 (3), p.335-344

2017

Volltextzugriff (PDF)

FANCI Regulates Recruitment of the FA Core Complex at Sites of DNA Damage Independently of FANCD2

PLoS genetics, 2015-10, Vol.11 (10), p.e1005563-e1005563

2015

Volltextzugriff (PDF)

Ubiquitination-Linked Phosphorylation of the FANCI S/TQ Cluster Contributes to Activation of the Fanconi Anemia I/D2 Complex

Cell reports (Cambridge), 2017-06, Vol.19 (12), p.2432-2440

2017

Volltextzugriff (PDF)

Interactions between MYC and transforming growth factor alpha alter the growth and tumorigenicity of liver progenitor cells

Carcinogenesis (New York), 2007-12, Vol.28 (12), p.2624-2631

2007

Volltextzugriff (PDF)

CTDP1 regulates breast cancer survival and DNA repair through BRCT-specific interactions with FANCI

Cell death discovery, 2019-06, Vol.5 (1), p.105-17, Article 105

2019

Volltextzugriff (PDF)

CPX-351, a Dual-Drug Liposomal Formulation, Alleviates the Cardiotoxicity of Daunorubicin and Cytarabine to Induced Human Pluripotent Stem Cell-Derived Cardiomyocytes

Blood, 2021-11, Vol.138 (Supplement 1), p.4352-4352

2021

Volltextzugriff (PDF)

Lower-Intensity CPX-351 + Venetoclax for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Post Hoc Analysis By Disease Risk Subgroups

Blood, 2022-11, Vol.140 (Supplement 1), p.3280-3281

2022

Volltextzugriff (PDF)

V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia

Blood, 2020-11, Vol.136 (Supplement 1), p.26-28

2020

Volltextzugriff (PDF)

Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results

Blood, 2021-11, Vol.138 (Supplement 1), p.2316-2316

2021

Volltextzugriff (PDF)

Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.1268-1268

2021

Volltextzugriff (PDF)

Disparate Requirements for the Phosphorylation of Distinct Sites on the Fanconi Anemia Group I Protein

Blood, 2014-12, Vol.124 (21), p.358-358

2014

Volltextzugriff (PDF)

V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type

Blood, 2022-11, Vol.140 (Supplement 1), p.3312-3314

2022

Volltextzugriff (PDF)

136 - CPX-351, a Dual-Drug Liposomal Formulation, Alleviates the Cardiotoxicity of Daunorubicin and Cytarabine to Induced Human Pluripotent Stem Cell-Derived Cardiomyocytes

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S110-S110

2022

Volltextzugriff (PDF)

CPX-351, a Dual-Drug Liposomal Formulation, Alleviates the Cardiotoxicity of Daunorubicin and Cytarabine to Induced Human Pluripotent Stem Cell-Derived Cardiomyocytes

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S110

2022

Volltextzugriff (PDF)

153 - Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S125-S125

2022

Volltextzugriff (PDF)

Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S125

2022

Volltextzugriff (PDF)

FANCI Regulates Recruitment of the FA Core Complex at Sites of DNA Damage Independently of FANCD2: e1005563

PLoS genetics, 2015-10, Vol.11 (10)

2015

Volltextzugriff (PDF)

High quality 16 kb/s voice transmission

ICASSP '76. IEEE International Conference on Acoustics, Speech, and Signal Processing, 1976, Vol.1, p.244-246

1976

Volltextzugriff (PDF)

Feature selection via dynamic programming for text-independent speaker identification

IEEE transactions on acoustics, speech, and signal processing, 1978-10, Vol.26 (5), p.397-403

1978

Volltextzugriff (PDF)

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis

The Lancet global health, 2014-02, Vol.2 (2), p.e106-e116

2014

Volltextzugriff (PDF)

Testing of a Hinged Wingtip Device for Gust Loads Alleviation

Journal of aircraft, 2018-09, Vol.55 (5), p.2050-2067

2018

Volltextzugriff (PDF)

Understanding the gut microbiota and sarcopenia: a systematic review

Journal of cachexia, sarcopenia and muscle, 2021-12, Vol.12 (6), p.1393-1407

2021

Volltextzugriff (PDF)

Best Performance Parameters of HR‐pQCT to Predict Fragility Fracture: Systematic Review and Meta‐Analysis

Journal of bone and mineral research, 2021-12, Vol.36 (12), p.2381-2398

2021

Volltextzugriff (PDF)

Pathology and genetics of phaeochromocytoma and paraganglioma

Histopathology, 2018-01, Vol.72 (1), p.97-105

2018

Volltextzugriff (PDF)

Incidence and progression of diabetic retinopathy: a systematic review

The lancet. Diabetes & endocrinology, 2019-02, Vol.7 (2), p.140-149

2019

Volltextzugriff (PDF)

1 – 25 von 650

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(571)
Mit Volltextzugriff
(570)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Recent insights into the molecular basis of Fanconi anemia: genes, modifiers, and drivers

FANCI Regulates Recruitment of the FA Core Complex at Sites of DNA Damage Independently of FANCD2

Ubiquitination-Linked Phosphorylation of the FANCI S/TQ Cluster Contributes to Activation of the Fanconi Anemia I/D2 Complex

Interactions between MYC and transforming growth factor alpha alter the growth and tumorigenicity of liver progenitor cells

CTDP1 regulates breast cancer survival and DNA repair through BRCT-specific interactions with FANCI

CPX-351, a Dual-Drug Liposomal Formulation, Alleviates the Cardiotoxicity of Daunorubicin and Cytarabine to Induced Human Pluripotent Stem Cell-Derived Cardiomyocytes

Lower-Intensity CPX-351 + Venetoclax for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Post Hoc Analysis By Disease Risk Subgroups

V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia

Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results

Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial

Disparate Requirements for the Phosphorylation of Distinct Sites on the Fanconi Anemia Group I Protein

V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type

136 - CPX-351, a Dual-Drug Liposomal Formulation, Alleviates the Cardiotoxicity of Daunorubicin and Cytarabine to Induced Human Pluripotent Stem Cell-Derived Cardiomyocytes

CPX-351, a Dual-Drug Liposomal Formulation, Alleviates the Cardiotoxicity of Daunorubicin and Cytarabine to Induced Human Pluripotent Stem Cell-Derived Cardiomyocytes

153 - Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial

Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial

FANCI Regulates Recruitment of the FA Core Complex at Sites of DNA Damage Independently of FANCD2: e1005563

High quality 16 kb/s voice transmission

Feature selection via dynamic programming for text-independent speaker identification

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis

Testing of a Hinged Wingtip Device for Gust Loads Alleviation

Understanding the gut microbiota and sarcopenia: a systematic review

Best Performance Parameters of HR‐pQCT to Predict Fragility Fracture: Systematic Review and Meta‐Analysis

Pathology and genetics of phaeochromocytoma and paraganglioma

Incidence and progression of diabetic retinopathy: a systematic review

Suchergebnisse filtern